# Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

> **NCT00241722** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 805 (actual)

## Conditions studied

- Bowel Dysfunction
- Constipation

## Interventions

- **DRUG:** Alvimopan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00241722
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-01
- **Primary completion:** 2007-02-01
- **Final completion:** 2007-02-01
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2017-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241722, "Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00241722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*